10-K/A: FibroBiologics Amends 10-K, Details Governance & Pay

FibroBiologics, Inc. filed an amendment to its 2025 Annual Report, providing detailed information on directors, executive compensation, security ownership, and related party transactions.

Summary

• FibroBiologics, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to include previously omitted Part III information.
• The amendment covers details on Directors, Executive Officers and Corporate Governance, Executive Compensation, Security Ownership of Certain Beneficial Owners and Management, Certain Relationships and Related Transactions, and Principal Accountant Fees and Services.
• No financial statements were included or amended, and no previously reported financial results were changed by this amendment.
• The aggregate market value of the company's voting and non-voting common equity held by non-affiliates was $21.6 million as of June 30, 2025.
• As of February 24, 2026, 67,594,722 shares of Common Stock were outstanding.
• The Compensation Committee determined that named executive officers would not receive bonus payments for 2025 performance due to the company's financial position, available cash, and upcoming liquidity needs.
• Audit fees paid to WithumSmith+Brown, PC were $328,339 for 2025 and $364,520 for 2024, with no audit-related or tax fees in either year.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the explicit mention of liquidity needs leading to the non-payment of executive bonuses, which overshadows the routine nature of governance disclosures and the recent capital raise.

Positives

• The company successfully completed a securities purchase agreement with Golden Knight Incorporated, LP in November 2025, raising capital through the issuance of common stock and warrants.
• The Board has established an Audit Committee, Compensation Committee, and Governance and Nominating Committee, with independent members meeting Nasdaq and SEC requirements.
• The company has adopted a Code of Ethics and Business Conduct and insider trading policies to promote compliance and good governance.

Negatives

• Named executive officers did not receive bonus payments for 2025 performance, which the Compensation Committee attributed to the company's financial position, available cash, and upcoming liquidity needs.
• The percentage change in the closing market price of securities underlying executive option awards granted on March 26, 2025, showed a decrease of 4.44% between the trading day immediately prior to and following the disclosure of material non-public information.

Risks

• Forward-looking statements contained in the 2025 Annual Report and this Amendment are subject to known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially from projections.
• The company's ability to fund future operating expenses and capital expenditure requirements depends on estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.

Future Outlook

This amendment primarily provides historical governance and compensation information and does not contain new forward-looking statements or guidance regarding the company's future operations, financial position, or strategic plans beyond the general disclaimer about the inherent uncertainties of forward-looking statements.

Management Comments

• The Compensation Committee recognized the named executive officers' 2025 achievements in the face of limited resources, both human capital and financial, despite determining no bonus payment for 2025 performance.

Industry Context

StockSavvy.ai notes that the detailed disclosure of executive compensation and corporate governance practices, while standard for SEC filings, provides transparency crucial for investors in the biotechnology sector, where R&D timelines and capital needs are significant. The non-payment of executive bonuses due to liquidity concerns, even with acknowledged achievements, highlights the financial pressures common in clinical-stage biotech companies, which often operate without significant revenue streams.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Related Party Transactions

• In May 2021, the company issued Series A Preferred Stock to FibroGenesis (its former parent company) in exchange for a Patent Assignment Agreement and an Intellectual Property Cross-License Agreement. These shares were later cancelled upon the Direct Listing.
• In January 2024, 2,500 shares of Series C Preferred Stock were issued to Pete O'Heeron, the Chairperson and CEO, for no consideration. Each share carries 13,000 votes, giving Mr. O'Heeron significant voting power, though subject to an irrevocable proxy to the Board.
• In July 2022, the company loaned $300,000 to FibroGenesis at 0% interest, which was fully repaid in April 2023.
• In January 2023, the company entered into an Agreement Regarding Right of First Negotiation (ROFN Agreement) with FibroGenesis, paying $2.8 million based on gross proceeds from equity investments through January 31, 2024.
• In December 2021, $1.3 million of convertible promissory notes (2021 Notes) were issued to investors, some of whom hold more than 5% of capital stock. These converted to Series B Preferred Stock in April 2023.
• In January and April 2022, $4.3 million of convertible promissory notes (2022 Notes) were issued to investors, some of whom hold more than 5% of capital stock. These converted to Series B Preferred Stock between February and June 2023.
• On November 18, 2025, the company entered into a securities purchase agreement with Golden Knight Incorporated, LP, which became a beneficial owner of more than 5% of the company's common stock through the purchase of common stock and warrants.
• On January 14, 2026, the company issued a $400,000 note receivable to Golden Knight Incorporated, LP, due January 14, 2027, with a 3.63% interest rate.

Stakeholder Impact

• Shareholders: The issuance of Series C Preferred Stock to the CEO with significant voting power (13,000 votes per share) could dilute the voting influence of common shareholders, although it is subject to an irrevocable proxy to the Board. The recent capital raise from Golden Knight Incorporated, LP provides funding but also introduces a new significant shareholder.
• Executive Officers: The non-payment of 2025 performance bonuses due to liquidity concerns directly impacts executive compensation, potentially affecting morale and retention, despite the Compensation Committee acknowledging their achievements.
• Employees: Participation in the Insperity 401(k) retirement savings plan and health/welfare plans provides standard benefits, contributing to employee well-being and retention.

Next Steps

• The company intends to disclose future amendments to its Code of Ethics and Business Conduct, and waivers granted to executive officers and directors, on its website within four business days following the amendment or waiver.

Key Dates

Recommendation

This 10-K/A filing primarily provides detailed governance, compensation, and related party transaction information, rather than new operational or financial performance data. While the non-payment of executive bonuses due to liquidity concerns is a negative signal, the recent capital raise provides some financial stability. Without a comprehensive view of the company's financial statements and operational progress, a definitive 'buy' or 'sell' recommendation is premature. Investors should 'hold' and await the full 2025 Annual Report and subsequent operational updates to assess the company's long-term prospects and financial health more thoroughly.

Keywords

SEC filing, 10-K/A, corporate governance, executive compensation, director compensation, security ownership, related party transactions, stock options, biotechnology, cell therapy, Nasdaq